Incidence of hepatitis B reactivation following Rituximab therapy.
Hanbali
Amr
A
Division of Hematology/Oncology, Department of Medicine, Henry Ford Hospital, Detroit, MI, USA.
Khaled
Yasser
Y
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D015994:Incidence; D008824:Michigan / Q000453:epidemiology; D012189:Retrospective Studies; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab